(Alliance News) - GlaxoSmithKline PLC on Wednesday said that Moncef Slaoui, chair of investee Galvani Bioelectronics, has been fired following allegations of sexual harassment and inappropriate conduct.
The termination, effective immediately, relates to allegations of Slaoui's conduct several years ago when he was an employee of GSK. An ongoing investigation substantiated the allegations, GSK said. GSK has a majority stake in Galvani.
Slaoui has been replaced as chair by Christopher Corsico, senior vice president of development at GSK.
GSK called Slaoui's behaviour "wholly unacceptable" and contrary to its values. "Sexual harassment and any abuse of leadership position are strictly prohibited and will not be tolerated," GSK said.
Slaoui was chair of GSK's vaccine unit before leaving in 2017 after 30 years at the company. He was head of the US Covid-19 vaccine programme Operation Warp Speed until January.
Hertfordshire-based Galvani, a medical research company, was formed in 2016 as a partnership between GSK and Alphabet Inc subsidiary Verily Life Sciences.
GSK shares closed down 1.0% at 1,284.80 pence in London.
By Ivan Edwards; ivanedwards@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)